S
Scion Neurostim
Committed to developing a home use, non-invasive treatment for Parkinson’s disease
About Scion Neurostim
Scion NeuroStim, Inc. operates as a medical device company, directing its efforts toward developing non-invasive neuromodulation technologies for patients with central nervous system diseases and disorders. The company, initially formed in 2007 and headquartered in Durham, North Carolina, is a privately held entity. A significant milestone was achieved in October 2023, when the company secured approximately $10 million in a Series C equity funding round involving 13 investors, adding to previous funding rounds.
The company’s core business revolves around the manufacturing and development of neurostimulator devices designed to be easy to use. Its product pipeline is built on stimulating innate protective pathways to manage conditions like pain. One of its key products is the TNM™ Device, which utilizes thermal vestibular stimulation through earpieces to treat headache and migraine. This device, which looks like a pair of headphones, delivers controlled thermal waveforms to modulate neural areas, including the brainstem. In 2018, the FDA granted marketing authorization for the TNM™ device for the prophylactic treatment of episodic migraine in patients aged 12 and older. The technology is based on the principle of caloric vestibular stimulation.
Scion NeuroStim is also actively engaged in clinical trials to expand the application of its technology. One area of focus is Parkinson's disease, where studies have explored the device's potential to improve both motor and non-motor symptoms as an adjunctive therapy to standard care. A study on Parkinson's disease dementia (PDD) aims to evaluate the safety and feasibility of the device for improving cognitive function. The company holds a substantial intellectual property portfolio with numerous patents granted and pending in the U.S. and internationally. While some devices are authorized for specific uses, others, like the TNM™ Device 4.0, are designated as Breakthrough Devices by the FDA and are currently limited to investigational use in clinical trials. Key figures associated with the company include directors Lanty Smith and Steven Bischoff, Chief Medical Officer Dr. Lesco Rogers, and CTO/COO Robert Black.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 53.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Neurology, Alzheimers Disease, Chronic Disease, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2023 | $10M | $40M | Undisclosed | ↗ |
| GRANTOther financing | Jan 2010 | $40K | — | NC IDEA | ↗ |
Growth signals
Latest recorded traffic for Scion Neurostim is 180 monthly website visits, down 18.2% over the last three months. Scion Neurostim's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Scion Neurostim in the Durham ecosystem
The Scion Neurostim office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
NC IDEA
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scion Neurostim on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scion Neurostim’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









